Nautilus Biotechnology, Inc.

NasdaqGS NAUT

Nautilus Biotechnology, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024

Nautilus Biotechnology, Inc. Free Cash Flow Per Share is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Nautilus Biotechnology, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.40, a -2.66% change year over year.
Nautilus Biotechnology, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.39, a -13.56% change year over year.
Nautilus Biotechnology, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.35.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqGS: NAUT

Nautilus Biotechnology, Inc.

CEO	Mr. Sujal M. Patel
IPO Date	Aug. 7, 2020
Location	United States
Headquarters	2701 Eastlake Avenue East
Employees	161
Sector	Technology
Industries Big Data 3D Printing Biotechnology Credit Cards & Payments Database Fintech Pharmaceuticals

Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Key trends

Past 5 years